Buscador de publicaciones<< Volver
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Théroux P, Wiviott SD, Strony J, Murphy SA
Vorapaxar in the secondary prevention of atherothrombotic events.
N. Engl. J. Med.. 2012 Apr;366(15):1404-13, PMID: 22443427
Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1.
MEDICINE, GENERAL & INTERNAL
Una iniciativa de
